Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Cotinga Pharmaceuticals Inc COTQF

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up... see more

GREY:COTQF - Post Discussion

View:
Post by DIYGuy on Jul 27, 2017 7:53pm

COTI 219

With no news we have to believe Phase 1 did not get the results they expected despite the misleading statements in their press releases. I read 70% of phase 1 trials move onto phase 2 but here we are over a year and a half and still have not determined the MTD. The restrictive rules of the FDA seems to only benefit the insiders. If there has been a toxic result we deserve to know when it occurred. 4 weeks after the reverse split we sit twisting in the wind. So, drift to nothing and let the sharks pick up cheap shares on the new PP on the promise of COTI219 or we are done.

The market does not like uncertainty and that is all we have. Should have ran for the hills when Danter resigned. 

How do the big funds like this $1.27. They must be lining up to pick up some shares. What a crock
Comment by Actuarial on Jul 28, 2017 9:44am
It took Kevetrin three years to complete phase 1 (August 2, 2012 - Feb 23, 2016) and similar time for Apr-246. COT was too optimstic on setting phase 1 completion time, which is their first mistake. COT did reverse split without positive news following the split, which is their second mistake. Comparing with their mistakes, our mistake is much bigger. We should have run when Danter resigned.
Comment by fatladysings321 on Jul 28, 2017 11:31am
Any new investor...even a bank...wants a great deal. Well they are going to get one helluva deal at these prices. The problem for us is obviously new management does not have a clue how to negotiate from a position of strength and now here we are. Once again, as in so many lousy stocks, the early investor gets screwed over. Thank you for your support. Now please bend over.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities